Mesoblast Investor Relations Material

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company's lead product candidate is remestemcel-L, an allogeneic mesenchymal precursor cell therapy that has completed Phase III clinical trial for use in steroid-refractory acute graft versus host disease. It also developed MSC-100-IV that is in Phase II clinical trial to investigate its effects on preventing organ dysfunction and death; MPC-150-IM to treat chronic heart failure; and MPC-06-ID to treat chronic low back pain due to advanced degenerative disc disease. In addition, it has licensed RemestemcelTM to JCR Pharmaceuticals Co., Ltd.; RemestemcelTM-L to JCR Pharmaceuticals Co., Ltd.; revascorTM through a partnership agreement with Pfizer Inc.; and MPC-300-IV through Cytori Therapeutics Inc. The company was founded in 2004 and is headquartered in Melbourne, Australia.